LITS

#4400
Lite Strategy, Inc. - Common Stock
0.9 9 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.99
0.99
Jahresspanne
0.69
3.23
Tagesänderung
+1.02%
Monatliche Änderung
+2.06%
6 month change
-8.33%
Jahresänderung
-66.78%
Vorheriger Schlusskurs
0.9 8
Open
0.9 9
Tief
0.9 9
Hoch
0.9 9
Volumen
3
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Lite Strategy, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q3 FY2026
Lite Strategy, Inc. quarterly report, Q3 FY2026
10-Q
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K

2025

Quarterly report, Q2 FY2025
Lite Strategy, Inc. quarterly report, Q2 FY2025
10-Q
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K

Lite Strategy, Inc. current report, Q3 FY2025

Full document

Business Context and Reporting Period

This Form 8-K is filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on July 30, 2025, reporting events occurring on July 24, 2025. The company is a Delaware corporation headquartered in San Diego, California, with common stock (Symbol: MEIP) listed on The Nasdaq Stock Market LLC.

Key Financial Metrics

This filing reports a specific capital transaction rather than comprehensive financial statements. Key metrics include:

  • Transaction Type: Exercise of pre-funded warrants.
  • Shares Issued: 2,084,509 shares of Common Stock.
  • Cash Proceeds: $208.45 (aggregate exercise price).
  • Offering Price: $3.4199 per Pre-Funded Warrant (original issuance).
  • Revenue, Profit, Cash Flow, Debt, Liquidity: The filing text does not provide a clear value for these general financial metrics.

Material Changes

The material change reported is the issuance of 2,084,509 shares of Common Stock to an investor following the exercise of pre-funded warrants. This transaction was part of a private placement offering (PIPE Offering) initiated on July 17, 2025, with the warrants originally issued on July 22, 2025. The transaction was executed under the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D.

Guidance, Outlook, and Risks

The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure regarding the unregistered nature of the securities sale. The document focuses solely on the mechanics of the warrant exercise and the legal basis for the exemption from registration.

Investor Verification Checklist

  • Verify the total number of shares outstanding post-transaction to assess dilution impact.
  • Confirm the identity of the investor exercising the warrants and their total commitment under the July 17, 2025 PIPE Offering.
  • Review the full text of the Pre-Funded Warrant (Exhibit 4.1 referenced in the July 22, 2025 filing) for terms regarding remaining unexercised warrants.
  • Check subsequent filings for the total cash proceeds raised from the full PIPE Offering, as this filing only covers a nominal exercise fee.